Find your next paid study

Astrocytoma, IDH-Mutant, Grade 3

Mayo ClinicNCT07301268

Phase 3

Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas

This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed…

Alliance for Clinical Trials in OncologyNCT07215910

Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed Cancer+12 more

Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatme…

National Institute of Neurological Disorders and Stroke (NINDS)NCT07416188

~$10 – $5,625

IDH1 wt AlleleRecurrent Anaplastic AstrocytomaRecurrent Glioblastoma+2 more

Phase I Clinical Trial of Allogeneic Bone Marrow Human Mesenchymal Stem Cells Loaded With A Tumor Selective Oncolytic Adenovirus, DNX-2401, Administered Via Intra-Arterial Injection in Patients With Recurrent High-Grade Glioma

This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurren…

M.D. Anderson Cancer CenterNCT03896568

Diffuse Astrocytoma, IDH-MutantGlioblastoma, IDH-wildtypeBrain Metastases, Adult+18 more

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 al…

GliomaGlioblastomaGBM+5 more

~$10 – $8,750

Phase 2

A Phase II Study of Elderly and Frail Patients With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® (ENDURANCE Trial)

This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed …

University of California, IrvineNCT07821112

Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III

A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide …

Debiopharm International SANCT05765812

~$10 – $7,500

Phase 2

A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only trea…

Grade 2 IDH1-mutant GliomaGrade 3 IDH1-mutant GliomaGlioma+5 more

Nuvation Bio Inc.NCT07703436

~$10 – $8,750

Phase 2

VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is…

GlioblastomaAstrocytoma, IDH-Mutant, Grade 4

Inova Health Care ServicesNCT07831369

~$10 – $7,500

Recurrent High Grade GliomaAnaplastic AstrocytomaAnaplastic Oligodendroglioma+2 more

A Phase I Study of Metronomic Temozolomide With Abexinostat (PCI-24781) for Patients With Recurrent High Grade Glioma

Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years. Th…

University of NebraskaNCT05698524

Phase 3

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with n…

Low Grade AstrocytomaLow Grade GliomaMetastatic Low Grade Astrocytoma+3 more

National Cancer Institute (NCI)NCT04166409

~$10 – $5,625

Observational

FearLess in Neuro-Oncology

The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist…

Primary Malignant Brain TumorGlioblastoma (GBM)Astrocytoma+2 more